Equillium reports third quarter 2020 financial results and business highlights

La jolla, calif., nov. 10, 2020 (globe newswire) -- equillium, inc. (nasdaq: eq), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced financial results for the third quarter 2020.

EQ Ratings Summary

EQ Quant Ranking